Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NuuVim vs Wellorithm

NuuVim
Graded #100

Higher grade

vs+22.599999999999994
Wellorithm
Graded #486

Lower grade

The verdict

NuuVim takes it — 71.1/100 to 48.5/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +67
97
30
Dose & formulationNuuVim +4
96
92
Clinical oversightNuuVim +14
42
28
Labs & monitoringNuuVim +10
50
40
FulfillmentWellorithm +1
61
62
Contract termsNuuVim +10
55
45
NuuVim · left barWellorithm · right bar

The numbers

MetricNuuVimWellorithm
WeighScore71.1/10048.5/100
GradeCC
Scorecard rank#100#486
Semaglutide$79/mo (all doses, compounded)Pricing not published
Tirzepatide$133/mo (all doses, compounded)Pricing not published
CoverageCoverage not published49 states (not Louisiana)
Brand-name accessYesYes
Oral / sublingualYesYes
NuuVim

Graded #100 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • No founder, CEO, medical director, or pharmacist-in-charge named
  • Refund and cancellation policy not surfaced on the site
  • Compounded medications are not FDA-approved
  • Doesn't disclose which pharmacy fills which drug or form
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Wellorithm

Graded #486 · C

Strengths

  • Both molecules in BOTH routes — compounded semaglutide and tirzepatide as injections and as oral dissolving tablets
  • Four branded pens on the same account: Mounjaro, Ozempic, Wegovy and Zepbound
  • Sermorelin offered alongside the GLP-1 line
  • 24/7 phone support on a published number

Where it loses points

  • No price appears anywhere on the public site — /pricing 404s and every product CTA leads to a 2-minute intake quiz, so no cost can be compared before signing up
  • The site contradicts itself on coverage: the homepage says "Serving All 50 States" while its own FAQ says 49 states and excludes Louisiana
  • The four clinicians presented as "board-certified obesity specialists" are listed as Cardiac Surgery, Pediatric Clinic, Gynecology and Cardiac Surgery — none in obesity medicine
  • "100% Customer Satisfaction" is stated as a headline fact and is not a substantiable claim

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard